NCT02226276
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 23 versions: 18 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Start date: Jan 7, 2015 to Feb 25, 2015
- Eligibility criteria expanded, about 14 words
- Study completion pushed from Sep 29, 2026 to Sep 7, 2027
- Minor Study completion date: Oct 30, 2025 to Sep 29, 2026v22
- Minor Study completion date: Dec 7, 2024 to Oct 30, 2025v21
- Minor Study completion date: Dec 30, 2023 to Dec 7, 2024v20
- Minor Study completion date: May 30, 2023 to Dec 30, 2023v19
Show 12 earlier versionsHide 12 earlier versions
- Minor Trial status: Completed to Active, Not Recruiting
- Study completion date: Dec 7, 2021 to May 30, 2023
- Notable Results first posted: Jul 20, 2022
- Primary endpoints: 4 to 2
- Trial status: Active, Not Recruiting to Completed
- Notable Primary and study completion dates: Dec 2020 to Dec 7, 2021v16
- Notable Primary and study completion dates: May 2020 to Dec 2020v15
- Notable Primary and study completion dates: Feb 2019 to May 2020v14
- Notable Primary and study completion dates: May 2018 to Feb 2019v12
- Minor Study description expanded, about 3 wordsv11
Notable Primary completion date: May 2017 to May 2018v9 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Study completion date: May 2018
- Start date: Jan 2015 to Jan 7, 2015
- Site details revised
- Notable Eligibility criteria expanded, about 14 words
- Primary completion date: Dec 2016 to May 2017
- Notable Eligibility criteria shortened, about 9 wordsv7
- Notable Eligibility criteria expanded, about 41 words
- Study description revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Dec 2014 to Jan 2015
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.
Radiation: fludeoxyglucose F 18, copper Cu 64-DOTA-trastuzumab
Procedures: positron emission tomography, computed tomography
Biologicals: trastuzumab, ado-trastuzumab emtansine
Other: laboratory biomarker analysis
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States